Introduction {#section0005}
============

The aetiological agent of the severe acute respiratory syndrome (SARS) is a coronavirus (SARS-CoV) which was responsible for causing a worldwide pandemic of lower respiratory tract infection between November 2002 and July 2003 ([@bib6], [@bib21], [@bib27], [@bib32]). During this time, there were approximately 8100 probable SARS cases and approximately 800 recorded fatalities (<http://www.wpro.who.int/sars/>). Rapid identification of individuals presenting with the disease as well as appropriate nursing techniques and quarantine procedures allowed the outbreak to be controlled by July of 2003. There have since been smaller outbreaks of the disease, but these have been contained with minimal secondary transmission. In the clinic, SARS-CoV infection presents as atypical pneumonia, with patients reporting symptoms of high fever (\>38 °C), dry cough, shortness of breath (dyspnea) and/or more severe breathing difficulties, which may occasionally require mechanical ventilation. The viral reservoirs are presumed to be bats ([@bib38], [@bib40]) and the palm civet cat has been implicated as a carrier of the virus, though there may also be other asymptomatic animal carriers ([@bib33]).

Of the several proteins found in the SARS coronavirus ([@bib35], [@bib43]), the large SARS-CoV spike glycoprotein (S) ([@bib36]) located on the virion surface is involved in both target cell attachment and fusion processes ([@bib42]). As with several coronaviruses, the spike glycoprotein can be proteolytically cleaved into two non-covalently associated glycoproteins: the virion-associated S1 (666 amino acid residues) containing the receptor attachment site and the transmembrane-anchored S2 (583 residues) responsible for fusion activity ([@bib1], [@bib9], [@bib24]).

The SARS-CoV S glycoprotein is a 1255-amino acid precursor polypeptide as deduced from the published genome sequence and has 23 potential *N*-linked glycosylation sites ([@bib7], [@bib27], [@bib32], [@bib41]). Previous studies have demonstrated that several of these sites are occupied and possess both complex-type and high-mannose type *N*-glycans ([@bib20], [@bib34], [@bib43]). However, full glycan analysis has not yet been performed.

SARS-CoV uses the angiotensin converting enzyme 2 (ACE2) as the primary receptor ([@bib4], [@bib23], [@bib30], [@bib39]) suggesting that oligomannose-containing *N*-glycans on the SARS-CoV S glycoprotein surface may be involved in mediating virus attachment to cells expressing this cell surface lectin. The C-type lectins DC-SIGN and L-SIGN (DC/L-SIGN) can enhance viral entry ([@bib28], [@bib42]). Site-directed mutagenesis analyses have identified seven glycosylation sites on the S protein critical for DC/L-SIGN-mediated virus entry. They include asparagine residues 109, 118, 119, 158, 227, 589, and 699, which are distinct from residues of the ACE2-binding domain (amino acids 318--510) ([@bib11]). Recently, L-SIGN (DC-SIGNR) has been shown to act as an entry receptor for SARS-CoV infection ([@bib19]), and its expression in lung alveolar and liver cells correlates with the disease pathogenesis observed in these organs in many SARS patients.

Given that oligomannose *N*-glycans may be involved in viral attachment to cells it is of interest to study the effects of modifications to the *N*-glycan profile with the object of possibly identifying therapeutic strategies. This report describes the first complete *N*-glycosylation analysis of SARS-CoV S glycoprotein produced in Vero E6 cells, a cell line derived from African green monkeys, and demonstrates the inhibitory effect of the α-glucosidase inhibitor *N*-butyl-deoxynojirimycin (*N*B-DNJ) on virus replication in this cell line.

Results and discussion {#section0010}
======================

Characterization of SARS-CoV spike protein {#section0015}
------------------------------------------

Viral proteins from purified viral particles were separated on 9% SDS-PAGE gels and stained with Coomassie blue ([Fig. 1](#fig1){ref-type="fig"} ). The proteins S, M and N were detected but the gel was not dense enough to detect the smaller (7 kDa) E protein. Western blotting using the SARS-CoV S glycoprotein antibody (Imgenex) confirmed the identity and molecular weight (180 kDa) of the S protein which was consistent with earlier reports ([@bib20], [@bib34], [@bib41]) and indicated the presence of the fully modified glycoprotein. There was no apparent difference in molecular weight between the glycoproteins produced with and without *N*B-DNJ.Fig. 1SDS-PAGE and western blotting analysis of purified SARS-CoV (strain Tor2) preparation. Left panel: 9% SDS-PAGE analysis of SARS-CoV virion preparation. S = SARS-CoV spike glycoprotein, N = SARS-CoV nucleoprotein, M = SARS-CoV matrix protein. Molecular weight markers are shown on the left. Right panel: Western blotting analysis of SARS-Co V virion preparation using an anti-SARS-CoV S antibody (Imgenex). U, untreated preparation; D, drug(*N*B-DNJ) treated preparation; M, mock infected preparation.

Identification of *N*-glycans {#section0020}
-----------------------------

The spike glycoprotein-containing band was cut from the gel for *N*-glycan analysis by in-gel PNGase F digestion followed by HPLC (as 2AB derivatives), exoglycosidase digestion, MALDI-TOF and nanoelectrospray MS/MS as described below. The HPLC trace of the SARS-CoV glycans obtained without *N*B-DNJ treatment is shown in [Fig. 2](#fig2){ref-type="fig"}a. Traces obtained before and after digestion with *Arthrobacter ureafaciens* sialidase ([Fig. 2](#fig2){ref-type="fig"}b) were virtually identical showing negligible incorporation of sialic acid in these glycans. Previous work ([@bib8]) has also shown a lack of sialylated *N*-glycans in Marburg virus grown in Vero E6 cells. The positive ion MALDI ([Fig. 3](#fig3){ref-type="fig"} ) and negative ion nanoelectrospray spectra were similar to each other and to the HPLC trace although more glycans were resolved by mass spectrometry. [Table 1](#tbl1){ref-type="table"} lists the identified glycans and their percentage of the total glycan pool as measured by MALDI-TOF MS and [Table 2](#tbl2){ref-type="table"} lists the percentage of various compound glycan types. Because a few of the glycans with different structures had the same mass and were, thus, not separated by mass spectrometry, the figures should be taken as approximate. Nevertheless, they reflect the composition of the mixture reasonably accurately.Fig. 2(a) NP-HPLC analysis of SARS-CoV S *N*-glycans. (b) HPLC analysis of SARS-CoV *N*-glycans following digestion with *Arthrobacter ureafaciens* sialidase (ABS, EC 3.2.1.18), (c) HPLC analysis following digestion with a mixture of ABS and bovine testis β-galactosidase (BTG, EC 3.2.1.23) and (d) HPLC analysis following incubation with a mixture of ABS, BTG and *Streptococcus pneumoniae* hexosaminidase (GUH, EC 3.2.1.30). The broken lines connecting the peaks in the various traces show movement of the peaks following digestion. Symbols used for the structural formulae: ■ = GlcNAc, ○ = mannose, ◊ = galactose, ![](fx1_lrg.gif) = fucose. The angle of the lines connecting the symbols shows the linkage with full and broken lines specifying β- and α-linkages, respectively. Further details are given in the paper by [@bib18].Fig. 3Positive ion MALDI-TOF mass spectrum (\[M+Na\]^+^ions) of the *N*-linked glycans obtained from the SARS-CoV spike protein. Peaks are identified in [Table 1](#tbl1){ref-type="table"} and the key to the structural symbols is in the legend to [Fig. 2](#fig2){ref-type="fig"} with the addition of □ = glucose. Glycan types are coloured: blue = high mannose, orange = hybrid, purple = monoantennary, red = biantennary, green = triantennary, pink = tetra-antennary.Table 1N-linked glycans with the masse of their \[M+Na\]^+^ and \[M+H~2~PO~4~\]^−^ ions.No.[a](#tblfn1){ref-type="table-fn"}GU[b](#tblfn2){ref-type="table-fn"}*m/z*CompositionStructure[e](#tblfn5){ref-type="table-fn"}MALDI (\[M+Na\]^+^)[c](#tblfn3){ref-type="table-fn"}Electrospray (\[M+H~2~PO~4~\]^−^)[d](#tblfn4){ref-type="table-fn"}HexHexNAcdHexFoundCalc.FoundCalc.1---1095.71096.0---1169.3420![](fx2_lrg.gif)[f](#tblfn7){ref-type="table-fn"}2---1136.91137.0---1210.4330![](fx3_lrg.gif)[f](#tblfn7){ref-type="table-fn"}36.171258.11258.11331.41331.4520![](fx4_lrg.gif)4---1283.81283.21356.61356.4331![](fx5_lrg.gif)5---1299.41299.2---1372.4430![](fx6_lrg.gif)[f](#tblfn7){ref-type="table-fn"}6---1339.91340.21413.51413.5340![](fx7_lrg.gif)77.051420.21420.21493.51493.5620![](fx8_lrg.gif)86.401444.71445.31518.51518.5431![](fx9_lrg.gif)9---1461.41461.31534.51534.5530![](fx10_lrg.gif)105.891486.41486.41559.51559.5341![](fx11_lrg.gif)11---1502.01502.41575.51575.5440![](fx12_lrg.gif)[f](#tblfn7){ref-type="table-fn"}127.941582.41582.41655.51655.5720![](fx13_lrg.gif)13---1607.71607.41680.51680.5531![](fx14_lrg.gif)14---1623.91623.41696.51696.5630![](fx15_lrg.gif)156.63\
6.811648.31648.51721.61721.6441![](fx16_lrg.gif)167.131664.41664.51737.61737.6540![](fx17_lrg.gif)176.17\
6.271689.91689.61762.61762.6351![](fx18_lrg.gif)186.501705.31705.51778.51778.6450![](fx19_lrg.gif)198.801744.71744.51817.61817.6820![](fx20_lrg.gif)20---1769.91769.61842.61842.6631![](fx21_lrg.gif)217.541810.81810.61883.61883.6541![](fx22_lrg.gif)22---1851.91851.71924.61924.6451![](fx23_lrg.gif)237.241867.71867.71940.61940.6550![](fx24_lrg.gif)246.861893.01892.71965.61965.7361![](fx25_lrg.gif)259.481907.51906.71979.61979.6920![](fx26_lrg.gif)267.652014.02013.82086.72086.7551![](fx27_lrg.gif)278.322029.82029.82102.72102.7650![](fx28_lrg.gif)288.022055.02054.92127.72127.7461![](fx29_lrg.gif)298.672176.22176.02248.72248.8651![](fx30_lrg.gif)30---2217.32217.02289.72289.8561![](fx31_lrg.gif)31---2232.82233.0---2305.8660![](fx32_lrg.gif)329.262379.62379.22451.82451.8661![](fx33_lrg.gif)33---2395.42395.2---2467.8760![](fx34_lrg.gif)349.952541.52541.32613.82613.9761![](fx35_lrg.gif)35---2744.12744.5---2817.0771![](fx36_lrg.gif)[f](#tblfn7){ref-type="table-fn"}36[g](#tblfn6){ref-type="table-fn"}10.27------------1020![](fx37_lrg.gif)[g](#tblfn6){ref-type="table-fn"}37[g](#tblfn6){ref-type="table-fn"}11.16------------1120![](fx38_lrg.gif)[g](#tblfn6){ref-type="table-fn"}38[g](#tblfn6){ref-type="table-fn"}11.80------------1220![](fx39_lrg.gif)[g](#tblfn6){ref-type="table-fn"}[^1][^2][^3][^4][^5][^6][^7]Table 2Percentages of various groups of *N*-glycan in SARS spike glycoprotein.Glycan type% TotalHigh-mannose---30Hybrid---28ComplexTotal42Biantennary19Triantennary12Tetraantennary11Truncated hybrid and complex (no galactose)---21

The glycans were identified by exoglycosidase digestion with monitoring by HPLC and by negative ion MS/MS of their \[M+H~2~PO~4~\]^−^ ions ([@bib12]) using electrospray sample introduction ([@bib13],[@bib14], [@bib17]). The HPLC traces obtained after ABS and bovine testis β-galactosidase (BTG) treatment ([Fig. 2](#fig2){ref-type="fig"}c) confirmed attachment of galactose at the non-reducing termini of the glycan antenna. Further incubation with hexosaminidase ([Fig. 2](#fig2){ref-type="fig"}d) reduced the profile to Man~3~GlcNAc~2~, Man~3~GlcNAc~2~Fuc~1~ and a series of unaffected high-mannose glycans. A few compounds were present at concentrations that were too weak to permit acquisition of informative MS/MS spectra. However, their structures could be deduced from the structures of related compounds, e.g., complex glycans with different numbers of galactose residues. Such compounds are identified in [Table 1](#tbl1){ref-type="table"}. Ion nomenclature in the following discussion follows that introduced by Domon and Costello ([@bib5]) as modified by Harvey et al. ([@bib15]) by the use of the subscript "R" to specify cleavages adjacent to the reducing-terminal GlcNAc residue and "R-1" to specify cleavages adjacent to the penultimate GlcNAc in order to avoid confusion by the subscript number changing as a function of antenna length.

High-mannose glycans {#section0025}
--------------------

High-mannose glycans containing from four to nine mannose residues were present in the glycan mixture ([Fig. 3](#fig3){ref-type="fig"}). Incubation with *Aspergillus saitoi a*-mannosidase (data not shown) reduced the larger compounds to Man~5~GlcNAc~2~ (compound **3**, [Table 1](#tbl1){ref-type="table"}) confirming the α-mannose linkages. The negative ion MS/MS spectra of the high-mannose glycans Man~5--9~GlcNAc~2~ (phosphate adducts) are shown in [Fig. 4](#fig4){ref-type="fig"} . The cross-ring ^2,4^A~R~ and ^2,4^A~R-1~ fragments together with the B~R-1~ ion at the high-mass end of the spectra define the 1→4-linked chitobiose core ([@bib13], [@bib17]) and the single C~1~ fragment at *m/z* 179 confirmed hexose (mannose) as the only non-reducing end residue. The ions towards the centre of the spectrum were mainly derived from the 6-antenna and allowed the distribution of the mannose residues between the two antennae to be determined. Predominant among these ions were the D-ion (formal loss of the 3-antenna from the C~R-1~ ion), the \[D-18\]^−^ ion and the ^O,3^A~R-2~ cross-ring cleavage fragment (core mannose residue) ([@bib13]). Thus, Man~5~GlcNAc~2~ (**3**) produced a spectrum with these ions at *m/z* 647, 629 and 575, respectively. Further confirmation of the substitution pattern was provided by the C~2~ ion at *m/z* 503 (three mannose residues). In the spectrum of Man~6~GlcNAc~2~ (**7**, [Fig. 4](#fig4){ref-type="fig"}b) the D, \[D-18\]^−^ and ^O,3^A~R-2~ ions were in the same position as in the spectrum of Man~5~GlcNAc~2~ showing that the sixth mannose was attached to the 3-antenna. These three diagnostic ions all shifted by 162 mass units to higher mass in the spectrum of Man~7~GlcNAc~2~ (**12**, [Fig. 4](#fig4){ref-type="fig"}c) showing that the seventh mannose was attached to the 6-antenna and the high abundance of the ion at *m/z* 485 was consistent with its location on the 6-branch of this antenna. This ion, termed D′, is thought to be equivalent to ion D as the result of the same substitution pattern of the branched mannose of the 6-antenna to that at the mannose of the core. This same pattern of D, \[D-18\]^−^, ^O,3^A~R-2~ and D′ ions was present in the spectrum of Man~8~GlcNAc~2~ (**19**, [Fig. 4](#fig4){ref-type="fig"}d) confirming attachment of the 8^th^ mannose to the 3-antenna and indicating that this compound had the classical d1,d3-substitution pattern. Finally, in the spectrum of Man~9~GlcNAc~2~ (**25**, [Fig. 4](#fig4){ref-type="fig"}e), the three 6-antenna-derived diagnostic ions shifted upwards by another 162 mass units to *m/z* 971, 953 and 899 as the result of the extra mannose residue in the 6-antenna. The presence of a second set of the D, \[D-18\]^−^, ^O,3^A~R-2~ ions at *m/z* 647, 629 and 575 in the spectrum of Man~7~GlcNAc~2~ (**12**) indicated the presence of a second isomer with three mannose residues in the 3-antenna. A fragmentation spectrum was not obtained for Man~4~GlcNAc~2~ (**1**).Fig. 4Negative ion MS/MS spectra of the \[M+H~2~PO~4~\]^−^ ions from the high-mannose glycans Man~5--9~GlcNAc~2~. Symbols for the structural diagrams are defined in the legend to [Fig. 2](#fig2){ref-type="fig"}. Ions are labelled according to the scheme introduced by Domon and Costello ([@bib5]).

Hybrid glycans {#section0030}
--------------

Hybrid glycans (numbers **9**, **13**, **14** and **20**, [Table 1](#tbl1){ref-type="table"}) were detected in the mass spectra but were not apparent in the HPLC trace of the total glycans. However, they became visible by HPLC following incubation with Jack bean α-mannosidase which removed all of the mannose residues from the 6-antenna to leave the chitobiose core and 3-antenna which consisted of GlcNAc and Gal-GlcNAc (data not shown). [Fig. 5](#fig5){ref-type="fig"} shows the negative ion MS/MS spectra of the hybrid glycans **9** ([Fig. 5](#fig5){ref-type="fig"}a) and **14** ([Fig. 5](#fig5){ref-type="fig"}b). The pattern of mannose substitution on the 6-antenna was determined by the masses of the D, \[D-18\]^−^, ^O,3^A~R-2~, D′ and \[D′-18\]^−^ ions in the negative ion MS/MS spectra as described above. The spectrum of the glycan corresponding to Hex~5~GlcNAc~3~ (**9**, [Fig. 5](#fig5){ref-type="fig"}a) showed the presence of two compounds as evidenced by the appearance of two sets of D and \[D-18\]^−^ ions (*m/z* 647/629 and 485/467) indicating three and two mannose residues respectively in the 6-antenna. The linkage of the mannose residue in the compounds with two mannose residues in the 6-antenna was not determined. Location of the fucose at position 6 of the terminal GlcNAc residue, when present, was determined by the masses of the abundant ^2,4^A~R~, ^2,4^A~R-1~ and B~R-1~ ions in the MS/MS spectra ([@bib14], [@bib17]) all of which were formed by loss of the fucose residue as the result of its attachment to the eliminated neutral fragment. Structures are shown in [Table 1](#tbl1){ref-type="table"}. No antenna-substituted fucose was detected in these or in the spectra of the complex glycans. The composition of the 3-antenna was specified by the mass of an E-type cross-ring fragment ion (substituents plus 101 mass units from the mannose residue ([@bib14], [@bib17])). These ions were of low abundance but were present at *m/z* 304 and 466 in the spectrum shown in [Fig. 5](#fig5){ref-type="fig"}a and at *m/z* 466 in [Fig. 5](#fig5){ref-type="fig"}b confirming the presence of GlcNAc and Gal-GlcNAc antennae respectively. The 3-antenna composition was further defined by an ^O,3^A cross-ring cleavage ion formed by fragmentation of the mannose residue and which appeared at 59 mass units above the mass of the substituents linked to the mannose (*m/z* 262 for a GlcNAc-containing antenna and *m/z* 424 for Gal-GlcNAc, see [Fig. 5](#fig5){ref-type="fig"}).Fig. 5Negative ion MS/MS spectra of the \[M+H~2~PO~4~\]^−^ ions from the hybrid glycans **9** and **14**. Symbols for the structural diagrams are defined in the legend to [Fig. 2](#fig2){ref-type="fig"}.

Complex glycans {#section0035}
---------------

Representative spectra are shown in [Fig. 6](#fig6){ref-type="fig"} . Bi-, tri- and tetra-antennary glycans were found, with and without core fucose and with and without a bisecting GlcNAc residue. Exoglycosidase digestion with ABS, BTG and GUH ([Fig. 2](#fig2){ref-type="fig"}) showed that the antennae consisted of galactose and GlcNAc only. Their negative ion MS/MS spectra were identical to those from reference standards. The branching structure of the triantennary glycan (**29**, [Fig. 6](#fig6){ref-type="fig"}c) was revealed by the mass of the E~3~ ion (*m/z* 831, the subscript "3" indicates its origin from the 3-antenna) ([@bib14], [@bib16]). This ion was also present in the spectrum of the tetra-antennary glycan (**34**, [Fig. 6](#fig6){ref-type="fig"}d) but, whereas the D and \[D-18\]^−^ ions from the 6-antenna in the spectrum of the triantennary glycan were at the same *m/z* values (688 and 670 respectively) as in the spectrum of the biantennary glycan ([Fig. 6](#fig6){ref-type="fig"}a), they moved to *m/z* 1053 and 1035 in the spectrum of the tetra-antennary glycan reflecting the presence of the additional Gal-GlcNAc moiety in the 6-antenna. An additional \[D-36\]^−^ ion at *m/z* 1017 was also characteristic of this branched structure on the 6-antenna. The fucose substitution pattern on the core GlcNAc residue was defined by the masses of the ^2,4^A~R~, ^2,4^A~R-1~ and B~R-1~ ions as described above. The occurrence of a bisecting GlcNAc residue was determined by the presence of an abundant \[D-221\]^−^ ion (e.g., *m/z* 670 in [Fig. 6](#fig6){ref-type="fig"}b), equivalent in mass to the \[M-18\]^−^ ion from the corresponding compound that did not contain a bisecting GlcNAc residue, as described earlier ([@bib17]).Fig. 6Negative ion MS/MS spectra of the \[M+H~2~PO~4~\]^−^ ions from (a) the fucosylated biantennary glycan **21**, (b) the bisected, fucosylated biantennary glycan **26**, (c) the fucosylated triantennary glycan **29** and (d) the fucosylated tetra-antennary glycan **34**. Symbols for the structural diagrams are defined in the legend to [Fig. 2](#fig2){ref-type="fig"}.

These basic complex structures were accompanied by relatively large amounts of analogues with fewer numbers of galactose residues ([Table 1](#tbl1){ref-type="table"}), confirmed by incubations with bovine testis β-galactosidase. Four representative spectra are shown in [Fig. 7](#fig7){ref-type="fig"} . All illustrated compounds contain a fucose residue attached to the core GlcNAc as shown by the masses of the ^2,4^A~R~, ^2,4^A~R-1~ and B~R-1~ ions as above. The spectrum of the biantennary glycan lacking both galactose residues (**10**, [Fig. 7](#fig7){ref-type="fig"}a) contained D and \[D-18\]^−^ ions at *m/z* 526 and 508, respectively, consistent with the absence of galactose in the 6-antenna. The C~1~ ion was at *m/z* 220 showing GlcNAc at the non-reducing terminus. Addition of one galactose residue ([Fig. 7](#fig7){ref-type="fig"}b) produced a mixed spectrum of glycans with the galactose attached to either antenna (**15**) as shown by the two pairs of D and \[D-18\]^−^ ions at *m/z* 526/508 (major isomer) and at *m/z* 688/670. Two C~1~ ions at *m/z* 179 and 220 confirmed both hexose (galactose) and GlcNAc, respectively, at the non-reducing terminus. The ^1,3^A~3~ ion at *m/z* 424 was consistent with the presence of a Gal-GlcNAc-containing antenna.Fig. 7Negative ion MS/MS spectra of the \[M+H~2~PO~4~\]^−^ ions from (a) the fucosylated biantennary glycan lacking galactose (**10**), (b) a mixture of the fucosylated biantennary glycan with one galactose residue on either antenna (**15**), (c) a mixture of the fucosylated triantennary glycan and the bisected biantennary glycan lacking galactose (**17**) and (d) a mixture of the fucosylated tetra-antennary glycan and the bisected triantennary glycan lacking galactose (**24**). Symbols for the structural diagrams are defined in the legend to [Fig. 2](#fig2){ref-type="fig"}.

Most of the other spectra from the glycans containing low galactose were of mixtures. They were interpreted by postulation of the expected ions, based on the structures of the identified fully galactosylated compounds and finding the relevant diagnostic ions in the spectra. Thus, the spectrum of the compounds having the composition Man~3~GlcNAc~5~Fuc~1~ (**17**, [Fig. 7](#fig7){ref-type="fig"}c) would be expected to contain contributions from the bisected biantennary glycan and the triantennary glycan, both lacking galactose. The spectrum contained a prominent ion at *m/z* 507 at the expected mass of the E ion from the triantennary glycan lacking galactose and D and \[D-18\]^−^ ions at *m/z* 526/508 from the 6-antenna. The enhanced relative abundance of the ion at *m/z* 508 suggested the presence of a small amount of the bisected biantennary glycan, this ion corresponding to \[D-221\]^−^. The two compounds (**24**) producing the spectrum in [Fig. 7](#fig7){ref-type="fig"}d were the degalactosylated tetra-antennary glycan and the bisected triantennary compound. The former compound produced the characteristic D, \[D-18\]^−^ and \[D-36\]^−^ triplet at *m/z* 729, 711 and 693 from the 6-antenna and the E ion at *m/z* 507. The other, minor compound was characterized by the \[D-221\]^−^ ion at *m/z* 508. The ion corresponding to the antenna mass plus 59 mass units (C~2~H~3~O~2~ from the attached mannose) also defined the antenna composition (the specific cross-ring cleavage producing these A-type ions varied with the linkage position of the antenna).

Effect of *N*B-DNJ treatment {#section0040}
----------------------------

### Effect of *N*B-DNJ against SARS-CoV infection {#section0045}

Following infection with SARS-CoV (strain Tor2, MOI = 10^-4^) and incubation with the iminosugar inhibitor *N*B-DNJ, the integrity of the Vero E6 cell monolayer was monitored daily by light microscopy. At *N*B-DNJ concentrations of 100 μg/mL and above, the cell monolayer remained intact and showed no signs of virally-induced cytopathic effects (CPE). However, no significant toxicity was seen at this drug concentration as shown by the XTT assay (data not shown).

### Effect of *N*B-DNJ treatment on N-glycan profiles {#section0050}

[Fig. 8](#fig8){ref-type="fig"}b shows the NP-HPLC profile of the *N*-glycans from the spike protein that was obtained in the presence of *N*B-DNJ at 100 μg/mL, the concentration that protected the cells against CPE. The glycans of higher molecular weight than were observed in the sample without *N*B-DNJ were identified by HPLC and exoglycosidase digestion (*A. ureafaciens* sialidase, bovine testis β-galactosidase *S. pneumonia N-*acetyl-hexosaminidase, Jack bean α-mannosidase and bovine kidney α-fucosidase) as Glc~3~Man~7~GlcNAc~2~, Glc~3~Man~8~GlcNAc~2~ and Glc~3~Man~9~GlcNAc~2~ showing that *N*B-DNJ at the concentration used (100 μg/mL) was able to partially inhibit glycan processing by blocking the first stage, namely removal of the terminal glucose residues from the 3-antenna. α-Mannosidase was, however, still able to remove the outer mannose residues from the 6-antenna to give the observed compounds. Although processing of the 3-antenna was blocked, complex glycans were still found in the profile. The most likely reason would be the presence of an *endo*-mannosidase that was able to split off Glc~3~Man from the 3-antenna. Such an enzyme has been reported from rats ([@bib25], [@bib26], [@bib29]) but there appears to be no information on its possible occurrence in the African green monkey. However, the high abundance of the peak labelled as 29 in [Fig. 8](#fig8){ref-type="fig"}b is accounted for by the isomer of Man~8~GlcNAc~2~ that has lost a mannose residue from the 3-antenna (same GU value as the fucosylated triantennary glycan) supporting this proposal.Fig. 8(a) NP-HPLC analysis of SARS-CoV *N*-glycans obtained without (a) and with (b) 100 μg/mL *N*B-DNJ. Peaks are identified in [Table 1](#tbl1){ref-type="table"}. The three glycans with residual glucose residues are highlighted.

Although the postulated endomannosidase activity permits extensive *N*-glycan processing with the production of complex glycans and a nearly normal profile in the presence of *N*B-DNJ, the drug prevents formation of the mono-glucosylated *N*-glycans that are necessary for binding to the chaperones calnexin and calreticulin that are essential for correct protein folding. Viral surface glycoproteins are dependent on such an interaction for correct folding ([@bib37]). Thus, α-glucosidase inhibition will prevent this interaction and potentially lead to regional or global glycoprotein misfolding. Therefore, the observation that the SARS-CoV S glycoprotein can undergo extensive *N*-glycan processing to complex structures in the presence of *N*B-DNJ does not necessarily correlate with proper glycoprotein folding. Unfortunately, the necessary conformationally sensitive anti-SARS-CoV S antibodies for testing this conclusion were not available at the time this study was performed. Improper folding induced by *N*B-DNJ could explain the protective effect of the drug towards viral infection but the ability to retain complex *N*-glycan processing could contribute to the drug\'s low cytotoxicity.

Conclusions {#section0055}
-----------

This study is the first to describe fully the range of *N*-glycans present on the SARS-CoV spike glycoprotein. They consisted mainly of high-mannose (Man~5--9~GlcNAc~2~, about 30% of the total glycans), hybrid (28%) and bi-, tri- and tetra-antennary complex glycans (42%) with and without both bisecting GlcNAc and core fucose. Complex glycans with fewer than the full complement of galactose residues were present in relatively high abundance with 49% of the complex glycans carrying no galactose. Sialylation was negligible. No evidence was found for glycans with *N*-acetyllactosamine extensions or with fucose attached to an antenna. The relatively high abundance of complex glycans lacking one or more of the normal galactose residues might indicate the involvement of the lectin, LSECtin in viral binding, as recently found for Ebola virus ([@bib31]).

Treatment with the glucosidase inhibitor *N*B-DNJ inhibited *N*-glycan processing as evidenced by the appearance in the profiles of glycans of composition Glc~3~Man~7--9~GlcNAc~2.~ However, some complex glycans still appeared in the glycan profile, suggesting the presence of an α-endomannosidase that was able to hydrolyse the Glc~3~-Man~3~ chain of the 3-antenna allowing attachment of GlcNAc in the first step towards complex glycan biosynthesis. Protection of cells against the cytopathic effects of the virus, possibly as the result of the inhibition of glycan processing, suggests a possible use of glucosidase inhibitors to treat SARS-CoV infections.

Materials and methods {#section0060}
=====================

Materials {#section0065}
---------

Methanol was obtained from BDH Ltd. (Poole, UK). Ammonium phosphate and 2,5-dihydroxybenzoic acid (DHB) were from Aldrich Chemical Co. Ltd. (Poole); water was distilled before use in a quartz apparatus. *N*B-DNJ was a gift from Monsanto Searle (St Louis, USA).

Preparation of SARS-CoV {#section0070}
-----------------------

All work with infectious SARS-CoV was performed in the high biocontainment laboratory of the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC). Vero E6 cells (ATCC CRL-1586, kidney epithelial cells derived from African green monkeys (*Cercopithecus aethiops*)) were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 10% fetal bovine serum (FBS) and subsequently infected with the Tor2 strain of the SARS-CoV ([@bib27]) at an MOI of 10^−4^ with and without the presence of different concentrations (0, 100, 500 and 1000 mg/mL) of *N*B-DNJ. After 1 h of virus adsorption, cells were washed 3 times and DMEM supplemented with 2% FBS (with and without *N*B-DNJ) was added. Forty-eight hours post-infection, the cell supernatant was harvested and cells were cleared by low-speed centrifugation. Virus particles were pelleted through a 20% sucrose cushion at 20,000 rpm for 2 h, washed with PBS and resuspended and inactivated in 1 × sample loading buffer with 1.5% SDS. Infectivity was further inactivated by heating the specimens at 100 °C for 15 min prior to removal from high biocontainment.

Assay for cellular toxicity {#section0075}
---------------------------

Vero E6 cells were cultured in 96-well plates in DMEM supplemented with 10% FBS. At 80% confluency the medium was removed and replaced with DMEM/2% FBS containing various concentrations (10--1000 μg/mL) of *N*B-DNJ, 5 wells per each concentration. Drug cytotoxicity was assessed on days 1, 2 and 3 post-treatment using the XTT metabolic assay (Roche, Laval, Canada) according to the manufacturer\'s directions.

SDS-PAGE analysis of SARS-CoV preparation {#section0080}
-----------------------------------------

The SARS-CoV preparation was analysed by 9% polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie blue staining. The stained protein band corresponding to the SARS-CoV S glycoprotein was cut from the gel for enzymatic digestion with peptide *N*-glycosidase F (PNGase F, Roche Diagnostics Ltd., Basel, Switzerland) and subsequent *N*-glycan analysis (see below).

Western blotting analysis of the SARS-CoV S glycoprotein {#section0085}
--------------------------------------------------------

To confirm that the band selected for *N*-glycan analysis was that corresponding to the SARS-CoV S glycoprotein, an anti-SARS-CoV S antibody was used in a western blotting protocol. Briefly, the SARS-CoV preparation was subjected to SDS-PAGE on a 9% gel and the proteins were transferred to PVDF membranes using the semi-dry transfer technique. The membranes were blocked in 5% milk solution in 1× phosphate-buffered saline (PBS) overnight then incubated with a mouse anti-SARS IgG1 (clone 16F1071, Imgenex, CA, USA) diluted 1:1000 in 3% milk solution at room temperature for at least 1 h. The membranes were washed three times in PBS--0.05% Tween-20 before 1 h incubation at room temperature with a horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody (Sigma Chemicals) diluted 1:1000 in 3% milk solution. The membranes were washed three times in PBS--0.05% Tween-20, then once with PBS. The SARS-CoV glycoprotein band was detected by developing the membranes using the ECL Western blotting detection kit (Amersham Biosciences, Little Chalfont, UK) according to the manufacturers instructions and followed by exposure to X-ray film (CL-X Posure film, Pierce).

*N*-glycan release using peptide *N*-glycosidase F {#section0090}
--------------------------------------------------

The procedure essentially followed that described by Küster et al. ([@bib22]). The glycoproteins were separated by SDS-PAGE with a BioRad Mini-Protean II apparatus with 80 × 80 × 0.75 mm plates and a 9% resolving gel. Developed gels were stained with Coomassie Blue R-250. The SARS-CoV S glycoprotein gel bands were excised from the gel and cut into pieces about 1 mm^2^, washed with 300 μL 20 mM NaHCO~3~ (BDH Limited, Poole, UK) and soaked in the buffer for 30 min. This procedure was repeated twice; on the third wash, 45 mM dithiothreitol (20 μL) was added and incubated for 30 min at 60 °C to reduce disulfide bonds. Iodoacetamide (100 mM; 20 μL) was added and the solution was incubated for 30 min in the dark. Then a 1:1 (v/v) solution (300 μL) of aqueous acetonitrile:20 mM NaHCO~3~, pH 7.0, was added and incubated for 60 min followed by vacuum drying. PNGase F (EC 3.2.2.18, 30 mL, 100 U/mL; Roche Diagnostics Ltd.) and NaHCO~3~ buffer (enough to cover the gel, 70--100 μL) was added to the dried gel pieces which were incubated at 37 °C for 12--16 h (overnight). The supernatant was retained and the gel was washed twice with water (200 μL), and then with acetonitrile (200 μL, Riedel de Häen Laboratory, Seelze, Germany); the washes were collected and desalted by incubation with 50 μL H^+^-activated AG-50, then centrifuged. The supernatant was filtered through 0.45 μm Millipore LH hydrophilic PTFE syringe-tip filter then vacuum dried in preparation for direct mass spectrometric analysis or 2-aminobenzamide (2AB) labelling followed by HPLC analysis. Samples for mass spectrometric analysis were further cleaned by drop dialysis with a Nafion 117 membrane ([@bib3]).

Glycan derivatisation with 2-aminobenzamide {#section0095}
-------------------------------------------

Glycans were labelled with 2AB by reductive amination ([@bib2]) using a 2AB labelling kit from Glyko (now part of Prozyme at Hayward, CA, USA). The 2AB labelling solution was prepared according to the manufacturer\'s instructions and stored at −20 °C. Five microliters of this solution was added to the dried sugars and incubated at 65 °C for 2 h. Residual 2AB reagent was removed by ascending paper chromatography on 3MM chromatography paper (Millipore, Watford, UK) in 100% acetonitrile. After 2 h, the sample was viewed under a UV light and the spot corresponding to the labelled sugars was cut from the paper and the sugars were eluted using four sequential aliquots of water (0.5 mL) into a nitric acid-washed glass tube. The eluted *N*-glycans were vacuum dried and then redissolved in water (200 μL).

Glycan sequencing using exoglycosidase digestion {#section0100}
------------------------------------------------

One to two picomoles of 2AB-labelled *N*-glycans were vacuum dried and incubated at 37 °C for 10 h in 50 mM sodium citrate buffer (pH 5.2) with exoglycosidases (Glyko) as follows: *Arthrobacter ureafaciens* sialidase (ABS, EC 3.2.1.18), a mixture of ABS and bovine testis β-galactosidase (BTG, EC 3.2.1.23), and a mixture of ABS, BTG and *Streptococcus pneumoniae N*-acetyl-hexosaminidase (GUH, EC 3.2.1.30) at the manufacturer\'s recommended concentrations. In a second experiment, glycans were incubated with Jack bean mannosidase (JBM, EC 3.2.1.24) 10 μL, 50 U/mL and *Aspergillus saitoi* α1-2-mannosidase (ASM), 2 μL, 1 mU/mL. The enzymes were removed after exoglycosidase digestions using washed (200 μL water, centrifugation at 7000 rpm for 10 min) nitrocellulose 0.45 μm microspin filters (Radleys, Saffron Walden, UK). The sample (10 μL) was added to the filter and centrifuged at 13,000 rpm for 3 min. The digestion tube was washed with water (20 μL) which was transferred to the filter and centrifuged at 13,000 rpm for 3 min. The filter was rinsed with water (100 μL) and centrifuged at 13,000 rpm for a further 3 min. The collected solution was vacuum dried and then redissolved in water (20 μL) for analysis by HPLC.

Normal-phase HPLC analysis {#section0105}
--------------------------

Acetonitrile (80 μL) was added to 10% of the sample (20 μL) and 95 μL was examined on a normal-phase (NP)-HPLC system (Waters Alliance 2690, Waters Corporation, Milford, MA, USA) fitted with a GlycoSep N column (Oxford GlycoSciences, Abingdon, UK) with a run time of 180 min ([@bib10]). The *N*-linked sugars eluted from the column with a retention time of between 40 and 120 min. Comparison with a dextran ladder allowed assignment of glucose unit (GU) values to each peak, which facilitated identification of the glycans present in the released pool.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) {#section0110}
-------------------------------------------------------------------------------------------

Positive ion MALDI-TOF mass spectra were obtained with a Waters-MS Technologies TofSpec 2E reflectron TOF mass spectrometer (Waters Ltd, Manchester). The pulse and acceleration voltages were 3 and 20 kV, respectively. Data acquisition and processing were performed with MassLynx software version 3.3. Samples were prepared by mixing an aqueous solution of the sample (0.5 μL) with a saturated solution of DHB in acetonitrile (0.3 μL) on the stainless steel MALDI target and allowing the mixture to dry under ambient conditions. The dried sample spot was then re-dissolved in ethanol (0.2 μL) and again allowed to dry.

Electrospray mass spectrometry {#section0115}
------------------------------

Electrospray mass spectrometry was performed with a Waters quadrupole-time-of-flight (Q-TOF) Ultima Global instrument in negative ion mode. Samples in 1:1 (v:v) methanol:water were infused through Proxeon nanospray capillaries (Proxeon Biosystems, Odense, Denmark). The ion source conditions were as follows: temperature, 120 °C; nitrogen flow, 50 L/h; infusion needle potential, 1.2 kV; cone voltage, 100 V; RF-1 voltage, 150 V. Spectra (2 s scans) were acquired with a digitization rate of 4 GHz and accumulated until a satisfactory signal:noise ratio had been obtained. The major ions were \[M+H~2~PO~4~\]^−^, the phosphate apparently arising from residual phosphate in the original sample, as observed previously from all glycan samples released as above. For MS/MS data acquisition, the parent ion was selected at low resolution (about 5 *m/z* mass window) to allow transmission of isotope peaks and fragmented with argon at a pressure (recorded on the instrument\'s pressure gauge) of 0.5 mBar. The voltage on the collision cell was adjusted with mass and charge to give an even distribution of fragment ions across the mass scale. Typical values were 80--120 V. Other voltages were as recommended by the manufacturer. Instrument control, data acquisition and processing were performed with MassLynx software version 4.0. Displayed spectra have been smoother using the Savitzky Golay algorithm (5 × 2) and abundant background ions at *m/z* 195, 291 and 344 have been removed for clarity.

We thank the Wellcome Trust and the Biotechnology and Biological Sciences Research Council for equipment grants to purchase the Q-TOF and TofSpec mass spectrometers, respectively. We thank the Public Health Agency of Canada (PHAC) for financial support.

[^1]: Peak numbers as in the MALDI-TOF spectrum ([Fig. 3](#fig3){ref-type="fig"}).

[^2]: Glucose unit.

[^3]: Average mass.

[^4]: Monoisotopic mass.

[^5]: Symbols used for the structural formulae: ■ = GlcNAc, ○ = mannose, ◊ = galactose, ![](fx1_lrg.gif) = fucose, □ = glucose. The angle of the lines connecting the symbols shows the linkage with full and broken lines specifying β- and α-linkages, respectively.

[^6]: In the presence of *N*B-DNJ only.

[^7]: Not confirmed by fragmentation.
